MET and breast carcinoma: To determine whether these effects of the c-Met/β1 complex were specific to more aggressive “basal” type triple-negative (ER, PR, and HER2 negative) breast cancer cells like MDA-MB-231, we engineered MCF7-iDimerize-c-Met-β1 cells from less aggressive MCF7 “luminal A” ER+PR+HER2– breast cancer cells (Supplemental Figure 3).